Journal
Pediatric Infectious Disease Journal
Publication Date
7-1-2023
Volume
42
Issue
7
First Page
557
Last Page
563
Document Type
Open Access Publication
DOI
10.1097/INF.0000000000003911
Rights and Permissions
Jackson CA, Newland J, Dementieva N, Lonchar J, Su FH, Huntington JA, Bensaci M, Popejoy MW, Johnson MG, De Anda C, Rhee EG, Bruno CJ. Safety and efficacy of ceftolozane/tazobactam plus metronidazole versus meropenem from a phase 2, randomized clinical trial in pediatric participants with complicated intra-abdominal infection. Pediatr Infect Dis J. 2023 Jul 1;42(7):557-563. doi: 10.1097/INF.0000000000003911. © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Recommended Citation
Jackson, Carl-Christian A.; Newland, Jason; Dementieva, Nataliia; Lonchar, Julia; Su, Feng-Hsiu; Huntington, Jennifer A.; Bensaci, Mekki; Popejoy, Myra W.; Johnson, Matthew G.; De Anda, Carisa; Rhee, Elizabeth G.; and Bruno, Christopher J., "Safety and efficacy of ceftolozane/tazobactam plus metronidazole versus meropenem from a phase 2, randomized clinical trial in pediatric participants with complicated intra-abdominal infection." Pediatric Infectious Disease Journal. 42, 7. 557 - 563. (2023).
https://digitalcommons.wustl.edu/oa_4/1959
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
